SESantiago Espinosa-Lugo

Santiago Espinosa-Lugo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Santiago Espinosa-Lugo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ocular Complications Related to Iris-Fixated Phakic Intraocular Lens Implantation: A Systematic Review and Meta-Analysis

    by Germán Mejía-Salgado, Blanca Aguilar-Barrera, Paula Alejandra Navarro, Diana Carolina Cortés-Jaimes, Ana María Núñez-Pardo, Juan Daniel Ribero, Santiago Espinosa-Lugo, Laura Daniela Rodríguez-Camelo, Joaquín Alonso Pérez-Vivas, Lizeth Catherine Rodríguez-Corredor, et al.

    Topic: This systematic review and meta-analysis evaluated the cumulative prevalence of ocular complications following implantation of Artisan ® /Verisyse ® iris-fixated phakic intraocular lenses in adult patients undergoing refractive surgery. Outcomes included postoperative ocular complications and longitudinal loss of endothelial cell density (ECD). Clinical relevance: Phakic intraocular lenses are widely used to correct moderate-to-high refractive errors. Available evidence on complication rates is heterogeneous and often limited to narrative reports, hindering accurate risk counseling and long-term clinical decision-making. Methods: This study was conducted according to PRISMA guidelines and was registered in PROSPERO (CRD420251150677). Eligible studies included ≥10 eyes implanted with Artisan ® /Verisyse ® lenses reporting postoperative complications. Risk of bias was assessed using design-specific tools. Proportion meta-analyses were performed with subgroup analyses comparing real-world evidence studies versus clinical trials. ECD loss was analyzed from three months to 10 years post-implantation. Certainty of evidence was evaluated using GRADE. Results: Fifty-five studies were included. Iris atrophy was the most common complication (20.3%, 95% CI: 5.7-52.1). Other complications included pupil ovalization (7.6%, 95% CI: 4.8-12.5), progressive reduction in visual acuity (7.6%, 95% CI: 5.8-9.5), position-related complications (including rotation, dislocation, subluxation, and luxation) (6.7%, 95% CI: 1.9-33.4), uveitis (6.2%, 95% CI: 4.3-9.1), and halos (5.3%, 95% CI: 3.2-7.9). Ocular hypertension (4.7%, 95% CI: 2.4-7.9), cataract (2.8%, 95% CI: 1.6-3.5), corneal decompensation (2.6%, 95% CI: 1.8-6.5), and retinal detachment (1.1%, 95% CI: 0.7-1.3) occurred less frequently. Subgroup analyses showed higher rates of corneal decompensation in real-world studies (4.2% vs. 1.3%; p = 0.04) and traumatic position-related complications (5.0% vs. 0.8%; p = 0.02), whereas ocular hypertension was more frequent in clinical trials (14.1% vs. 2.3%; p < 0.01). ECD loss increased from 5.3% at 3 months to 15.8% at 10 years. Certainty of evidence ranged from very low to moderate, with substantial heterogeneity across outcomes. Conclusion: Despite overall acceptable safety, Artisan ® /Verisyse ® implantation is associated with measurable ocular complications and progressive ECD loss.